ClinicalTrials.gg
TerminatedNCT05573035Updated Jul 1, 2025

A Study to Investigate LYL845 in Adults With Solid Tumors

A Phase 1 interventional study of LYL845 in Melanoma, Non-small Cell Lung Cancer and Colorectal Cancer, sponsored by Lyell Immunopharma, Inc.. Terminated at 18 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-07-01.

Sponsored by Lyell Immunopharma, Inc. · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
Pipeline Reprioritization

From the registry’s dates

  • Primary completion was Jan 2025, 1 year 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
39
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,050 studies in Melanoma with a site in United States — 242 open to participants now, 437 under way, 32 of them phase 3. Melanoma · United States.

Enrollment
853rd of 1,750
39 · median 37
Started
2022
with 87 others
Phase 1
648 of 2,050
55 open now
Registered
1,781st of 2,050
by date

Among the 2,050 studies in Melanoma with a site in United States, this one is the 853rd largest by enrollment of the 1,750 interventional ones that give a count, is one of 88 that started in 2022, is one of 648 in phase 1, and was the 1,781st registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

242 of the 2,050 studies in Melanoma with a site in United States are open now. Recruiting first, the newest first:

237 more — sign in →

All 242 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,050 studies in Melanoma with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, multi-center, dose-escalation study with expansion cohorts, designed to evaluate the safety and anti-tumor activity of LYL845, an epigenetically reprogrammed tumor infiltrating lymphocyte (TIL) therapy, in participants with relapsed or refractory (R/R) metastatic or locally advanced melanoma, non-small cell lung cancer (NSCLC), and colorectal cancer (CRC).

Read the detailed description

This is an open-label, multi-center, dose-escalation study with expansion cohorts, designed to evaluate the safety and anti-tumor activity of LYL845, an epigenetically reprogrammed tumor infiltrating lymphocyte (TIL) therapy, in participants with relapsed or refractory (R/R) metastatic or locally advanced melanoma, non-small cell lung cancer (NSCLC), and colorectal cancer (CRC). During the dose-escalation phase of the study (Part A), participants with melanoma will be enrolled. Once a safe recommended Phase 2 dose range (RP2DR) has been established in Part A, enrollment will be expanded (Part B) to include additional participants with melanoma, NSCLC and CRC.

03

Conditions studied

  • Melanoma
  • Non-small Cell Lung Cancer
  • Colorectal Cancer

Keywords

  • TIL
  • tumor infiltrating lymphocyte
  • melanoma
  • non-small cell lung cancer
  • colorectal cancer
  • NSCLC
  • CRC
  • relapsed
  • refractory
  • locally advanced
  • advanced
  • metastatic
  • epigenetic
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years up to ≤ 75 years at the time of
  • Confirmed diagnosis of melanoma, non-small cell lung cancer (NSCLC), or colorectal cancer (CRC) that is or locally advanced or unresectable and is (R/R) after standard therapy for each tumor histology
  • Participants must have received prior systemic treatment for their metastatic disease or locally advanced disease based on tumor type as follows:
  • Melanoma: participants with disease progression following an (CPI)
  • NSCLC: participants with disease progression following at least 1 approved systemic therapy, including an immune CPI-containing regimen for appropriate patients or an approved targeted therapy for known molecular abnormalities if applicable to their disease
  • CRC: participants with disease progression following at least 1 , including a fluoropyrimidine with oxaliplatin or irinotecan. Microsatellite instability (MSI) high/mismatch repair deficient (dMMR) CRC participants must have disease progression following systemic therapy with immune CPIs.
  • including at least 1 lesion that is safely resectable AND a target lesion to measure response and an additional lesion for
  • (ECOG) performance status of 0 or 1
  • Adequate organ and marrow function
  • Women of must have a negative pregnancy test at screening
  • All participants must agree to practice highly effective methods of
  • Fully recovered from toxicity from prior systemic anticancer therapy

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with adoptive cellular therapy
  • Prior solid organ transplantation
  • Central nervous system (CNS) involvement of disease that is extensive, symptomatic or untreated, or patients with
  • Uncontrolled or symptomatic pleural effusion or ascites
  • Untreated or active systemic infection
  • Active disease requiring treatment or primary immunodeficiency syndrome
  • Systemic at a dose of >10 mg of prednisone or equivalent per day
  • Other primary within 3 years prior to enrollment
  • Impaired cardiac function or cardiovascular disease
  • Required chronic anticoagulation, such as warfarin, low molecular weight heparin, or Factor Xa inhibitors
  • Pregnant or nursing (lactating) women
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Experimental LYL845

    Epigenetically reprogrammed tumor infiltrating lymphocyte (TIL) therapy

    Biological: LYL845

Interventions

  • BiologicalLYL845

    LYL845 is an autologous tumor infiltrating lymphocyte (TIL) enhanced via Epi-R, a proprietary epigenetic reprogramming technology

06

What researchers measure

Primary outcomes

  1. Incidence of dose-limiting toxicities (DLTs)

    Evaluate incidence of dose-limiting toxicities (DLTs)

    Time frame: Up to 28 days

  2. Incidence of treatment-emergent adverse events (TEAEs)

    Evaluate incidence of treatment-emergent adverse events (TEAEs)

    Time frame: Up to 2 years

  3. Severity of treatment-emergent adverse events (TEAEs)

    Evaluate severity of treatment-emergent adverse events (TEAEs)

    Time frame: Up to 2 years

  4. Determine recommended Phase 2 Dose Range (RP2DR)

    Determine the recommended Phase 2 dose range (during dose-escalation phase)

    Time frame: Up to 2 years

Secondary outcomes

  1. Overall response rate (ORR) by RECIST, version 1.1

    Evaluate anti-tumor activity of LYL845 based on overall response rate (ORR) by RECIST, version 1.1

    Time frame: up to 2 years

  2. Duration of response (DOR)

    Evaluate duration of response (DOR)

    Time frame: up to 2 years

  3. Progression-free survival (PFS)

    Evaluate progression-free survival (PFS)

    Time frame: up to 2 years

  4. Overall survival (OS)

    Evaluate overall survival (OS)

    Time frame: up to 2 years

07

Study locations

18 sites
  • UC Davis Coomprehensive Cancer Center
    Sacramento, California 95817, United States
  • UCLA Medical Center
    Santa Monica, California 90404, United States
  • Stanford University
    Stanford, California 94305, United States
  • Yale Cancer Center, Yale University
    New Haven, Connecticut 06511, United States
  • Georgetown University
    Washington D.C., District of Columbia 20007, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Mayo Clinic Comprehensive Cancer Center
    Rochester, Minnesota 55905, United States
  • Hackensack Meridian Health Inc
    Hackensack, New Jersey 07601, United States
  • Rutgers Cancer Institute of New Jersey
    New Brunswick, New Jersey 08901, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Ohio State University Medical Center
    Columbus, Ohio 43210, United States
  • Oregon Health Sciences University
    Portland, Oregon 97239, United States
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15224, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75235, United States
  • Huntsman Cancer Institute at University of Utah
    Salt Lake City, Utah 84112, United States
  • Fred Hutchinson Cancer Center
    Seattle, Washington 98109, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2022 to primary completion in Jan 2025, 24 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2022
First posted
Oct 10, 2022
StartActual
Dec 19, 2022
Primary completionActual
Jan 9, 2025
CompletionActual
Jan 9, 2025
Last update
Jul 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05573035
Lead sponsor
Lyell Immunopharma, Inc.
Responsible party
Sponsor
First posted
Oct 10, 2022
Start date
Dec 19, 2022
Primary completion
Jan 9, 2025
Completion
Jan 9, 2025
Last update
Jul 1, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion